title: Treatments to support blood pressure increases bleeding and/or decreases survival in a rat model of closed head trauma combined with uncontrolled hemorrhage.
abstract: Hemorrhagic hypotension may aggravate the detrimental effects of head trauma on neurologic outcome. Our study examined whether using phenylephrine or large volumes of saline IV to increase mean arterial blood pressure (MAP) to 70, 80, or 90 mm Hg during the combination of head trauma and uncontrolled hemorrhage would improve neurologic outcome. Rats were assigned to one of 17 groups. In Groups 1-5, the variables were head trauma (yes/no), hemorrhage (yes/no), 0 or 3 mL saline per milliliter of blood lost, and no target MAP. In Groups 6-11, hemorrhage was or was not combined with head trauma, and large volumes of saline were given IV to achieve target MAPs of 70, 80, or 90 mm Hg. Groups 12-17 were similar to Groups 6-11 except that phenylephrine was used rather than saline to achieve target MAPs. Saline increased blood loss at 2 h to approximately 16 and 25 mL at a MAP of 80 and 90 mm Hg respectively, increased (worsened) the neurodeficit score but not cerebral edema at 24 h, and decreased survival rate at 2 and 24 h. Because phenylephrine was fatal for 62 of 63 rats, group mean values for blood loss, neurodeficit score, and brain tissue specific gravity could not be calculated. We conclude that supporting MAP with either phenylephrine or large volumes of saline worsened the neurodeficit score and/or survival and did not affect cerebral edema formation in our rat model of head trauma combined with hemorrhage.
  
  
  CONCLUSIONS
  The results of this study indicate that maintaining mean arterial blood pressure at 70, 80, or 90 mm Hg with either phenylephrine or large volumes of saline worsened the neurodeficit score and/or survival and did not affect cerebral edema formation in our rat model of head trauma combined with hemorrhage.
authors.affiliation: Division of Anesthesiology, Ben-Gurion University of the Negev, Faculty of Health Sciences, Soroka Medical Center, Beer Sheva, Israel.
authors.forename: D
authors.initials: D
authors.lastname: Talmor
authors.forename: V
authors.initials: V
authors.lastname: Merkind
authors.forename: A A
authors.initials: AA
authors.lastname: Artru
authors.forename: O
authors.initials: O
authors.lastname: Shapiro
authors.forename: D
authors.initials: D
authors.lastname: Geva
authors.forename: L
authors.initials: L
authors.lastname: Roytblat
authors.forename: Y
authors.initials: Y
authors.lastname: Shapira
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D001921:Brain / Q000503:physiopathology; D001927:Brain Diseases / Q000209:etiology*; D001929:Brain Edema / Q000209:etiology / Q000503:physiopathology; D004195:Disease Models, Animal; D005440:Fluid Therapy; D016489:Head Injuries, Closed / Q000150:complications* / Q000503:physiopathology; D006470:Hemorrhage / Q000150:complications* / Q000503:physiopathology; D007022:Hypotension / Q000188:drug therapy* / Q000503:physiopathology; D007262:Infusions, Intravenous; D008297:Male; D010656:Phenylephrine / Q000627:therapeutic use; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013046:Specific Gravity; D015996:Survival Rate; D013997:Time Factors; D014662:Vasoconstrictor Agents / Q000627:therapeutic use; D014949:Wounds, Nonpenetrating / Q000150:complications / Q000503:physiopathology
chemical_list: D014662:Vasoconstrictor Agents; D010656:Phenylephrine